Prostratin exhibits both replication enhancing and inhibiting effects on FIV infection of feline CD4+ T-cells

Virus Research

Volumn 171, Issue 1, 2013, Pages 121-128

  Chan, Chi Ngai ^a   McMonagle, Elizabeth L ^a   Hosie, Margaret J ^a   Willett, Brian J ^a  

^a MRC UNIVERSITY OF GLASGOW CENTRE FOR VIRUS RESEARCH   (United Kingdom)

Author keywords

CD4+ T cells; FIV; HIV 1; IL 2; PKC; PMA; Prostratin; Protein kinase C

Indexed keywords

INTERLEUKIN 2; PHORBOL ESTER; PROSTRATIN; PROTEIN KINASE C INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CAT; CD4+ T LYMPHOCYTE; CELL VIABILITY; CONTROLLED STUDY; FELINE IMMUNODEFICIENCY VIRUS; FELINE IMMUNODEFICIENCY VIRUS INFECTION; FLOW CYTOMETRY; LENTIVIRUS INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; VIROGENESIS; VIRUS ENTRY; VIRUS REPLICATION;

ANIMALS; CATS; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELL PROLIFERATION; CELL SURVIVAL; HIV-1; HUMANS; IMMUNODEFICIENCY VIRUS, FELINE; INTERLEUKIN-2; LYMPHOCYTE DEPLETION; PHORBOL ESTERS; PROTEIN KINASE C; SIGNAL TRANSDUCTION; VIRUS REPLICATION;

FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MYA;

EID: 84872816672     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.11.004     Document Type: Article

References (33)

1. Biancotto A., Grivel J.-C., Gondois-Rey F., Bettendroffer L., Vigne R., Brown S., Margolis L.B., Hirsch I. Dual role of Prostratin in inhibition of infection and reactivation of human immunodeficiency virus from latency in primary blood lymphocytes and lymphoid tissue. Journal of Virology 2004, 78(19):10507-10515.
2. Bisset L.R., Lutz H., Boni J., Hofmann-Lehmann R., Luthy R., Schupbach J. Combined effect of zidovudine (ZDV), lamivudine (3TC) and abacavir (ABC) antiretroviral therapy in suppressing in vitro FIV replication. Antiviral Research 2002, 53(1):35-45.
3. Brooks D.G., Hamer D.H., Arlen P.A., Gao L.Y., Bristol G., Kitchen C.M.R., Berger E.A., Zack J.A. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003, 19(3):413-423.
4. Cheng G., Yu A., Malek T.R. T-cell tolerance and the multi-functional role of IL-2R signaling in T-regulatory cells. Immunological Reviews 2011, 241(1):63-76.
5. Gulakowski R.J., McMahon J.B., Buckheit R.W., Gustafson K.R., Boyd M.R. Antireplicative and anticytopathic activities of prostratin, a non-tumor-promoting phorbol ester, against human immunodeficiency virus (HIV). Antiviral Research 1997, 33(2):87-97.
6. Gustafson K.R., Cardellina J.H., McMahon J.B., Gulakowski R.J., Ishitoya J., Szallasi Z., Lewin N.E., Blumberg P.M., Weislow O.S. A nonpromoting phorbol from the Samoan medicinal plant Homalanthus nutans inhibits cell killing by HIV-1. Journal of Medicinal Chemistry 1992, 35(11):1978-1986.
7. Hosie M.J., Jarrett O. Serological responses of cats to feline immunodeficiency virus. Aids 1990, 4(3):215-220.
8. Isakov N., Altman A. Protein kinase C(theta) in T cell activation. Annual Review of Immunology 2002, 20:761-794.
9. Joshi A., Garg H., Tompkins M.B., Tompkins W.A. Different thresholds of T cell activation regulate FIV infection of CD4(+)CD25(+) and CD4(+)CD25(-) cells. Virology 2005, 335(2):212-221.
10. Korin Y.D., Brooks D.G., Brown S., Korotzer A., Zack J.A. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. Journal of Virology 2002, 76(16):8118-8123.
11. Kulkosky J., Culnan D.M., Roman J., Dornadula G., Schnell M., Boyd M.R., Pomerantz R.J. Prostratin: activation of latent HIV-1 expression suggests a potential inductive adjuvant therapy for HAART. Blood 2001, 98(10):3006-3015.
12. Lewin S.R., Evans V.A., Elliott J.H., Spire B., Chomont N. Finding a cure for HIV: will it ever be achievable?. Journal of the International Aids Society 2011, 14:4. 10.1186/1758-2652-14-4.
13. Liu W.S., Heckman C.A. The sevenfold way of PKC regulation. Cellular Signalling 1998, 10(8):529-542.
14. Martiny-Baron G., Kazanietz M.G., Mischak H., Blumberg P.M., Kochs G., Hug H., Marmé D., Schächtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. Journal of Biological Chemistry 1993, 268(13):9194-9197.
15. Miyazawa T., Furuya T., Itagaki S., Tohya Y., Takahashi E., Mikami T. Establishment of a feline T-lymphoblastoid cell line highly sensitive for replication of feline immunodeficiency virus. Archives of Virology 1989, 108(1-2):131-135.
16. Oswald-Richter K., Grill S.M., Leelawong M., Unutmaz D. HIV infection of primary human T cells is determined by tunable thresholds of T cell activation. European Journal of Immunology 2004, 34(6):1705-1714.
17. Pedersen N.C., Ho E.W., Brown M.L., Yamamoto J.K. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987, 235(4790):790-793.
18. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323(5919):1304-1307.
19. Romani B., Engelbrecht S. Human immunodeficiency virus type 1 Vpr: functions and molecular interactions. Journal of General Virology 2009, 90:1795-1805.
20. Rullas J., Bermejo M., Garcia-Perez J., Beltran M., Gonzalez N., Hezareh M., Brown S.J., Alcami J. Prostratin induces HIV activation and downregulates HIV receptors in peripheral blood lymphocytes. Antiviral Therapy 2004, 9(4):545-554.
21. Savarino A., Pistello M., D'Ostilio D., Zabogli E., Taglia F., Mancini F., Ferro S., Matteucci D., De Luca L., Barreca M.L., Ciervo A., Chimirri A., Ciccozzi M., Bendinelli M. Human immunodeficiency virus integrase inhibitors efficiently suppress feline immunodeficiency virus replication in vitro and provide a rationale to redesign antiretroviral treatment for feline AIDS. Retrovirology 2007, 4:79.
22. Shimojima M., Miyazawa T., Ikeda Y., McMonagle E.L., Haining H., Akashi H., Takeuchi Y., Hosie M.J., Willett B.J. Use of CD134 as a primary receptor by the feline immunodeficiency virus. Science 2004, 303(5661):1192-1195.
23. Sparger E.E., Shacklett B.L., Renshawgegg L., Barry P.A., Pedersen N.C., Elder J.H., Luciw P.A. Regulation of gene-expression directed by the long terminal repeat of the feline immunodeficiency virus. Virology 1992, 187(1):165-177.
24. Stevenson M., Stanwick T.L., Dempsey M.P., Lamonica C.A. HIV-1 replication is controlled at the level of T-cell activation and proviral integration. EMBO Journal 1990, 9(5):1551-1560.
25. Tan S.-L., Parker P.J. Emerging and diverse roles of protein kinase C in immune cell signalling. Biochemical Journal 2003, 376(3):545-552.
26. Tang H., Kuhen K.L., Wong-Staal F. Lentivirus replication and regulation. Annual Review of Genetics 1999, 33:133-170.
27. Thompson F.J., Elder J., Neil J.C. Cisregulation and transregulation of feline immunodeficiency virus - identification of functional binding-sites in the long terminal repeat. Journal of General Virology 1994, 75:545-554.
28. Wainberg M.A., Jeang K.T. 25 years of HIV-1 research - progress and perspectives. BMC Medicine 2008, 6:7.
29. Warrilow D., Gardner J., Darnell G.A., Suhrbier A., Harrich D. HIV type 1 inhibition by protein kinase C modulatory compounds. AIDS Research and Human Retroviruses 2006, 22(9):854-864.
30. Willett B.J., McMonagle E.L., Logan N., Schneider P., Hosie M.J. Enforced covalent trimerisation of soluble feline CD134 (OX40)-ligand generates a functional antagonist of feline immunodeficiency virus. Molecular Immunology 2009, 46(6):1020-1030.
31. Willett B.J., McMonagle E.L., Logan N., Spiller O.B., Schneider P., Hosie M.J. Probing the interaction between feline immunodeficiency virus and CD134 by using the novel monoclonal antibody 7D6 and the CD134 (OX40) ligand. Journal of Virology 2007, 81(18):9665-9679.
32. Willett B.J., Picard L., Hosie M.J., Turner J.D., Adema K., Clapham P.R. Shared usage of the chemokine receptor CXCR4 by the feline and human immunodeficiency viruses. Journal of Virology 1997, 71(9):6407-6415.
33. Williams S.A., Chen L.F., Kwon H., Fenard D., Bisgrove D., Verdin E., Greene W.C. Prostratin antagonizes HIV latency by activating NF-kappa B. Journal of Biological Chemistry 2004, 279(40):42008-42017.